Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
Medtronic
McKesson
Colorcon

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for IMO-2125


Email this page to a colleague

« Back to Dashboard

What is the drug development status for IMO-2125?

IMO-2125 is an investigational drug.

There have been 18 clinical trials for IMO-2125. The most recent clinical trial was a Phase 2 trial, which was initiated on May 30th 2018.

The most common disease conditions in clinical trials are Melanoma, Carcinoma, and Psoriasis. The leading clinical trial sponsors are Idera Pharmaceuticals, Inc., EMD Serono, and Bristol-Myers Squibb.

There are three US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for IMO-2125
TitleSponsorPhase
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 MelanomaIdera Pharmaceuticals, Inc.Phase 2
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 MelanomaA.J.M. van den EertweghPhase 2
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Bristol-Myers SquibbPhase 2

See all IMO-2125 clinical trials

Clinical Trial Summary for IMO-2125

Top disease conditions for IMO-2125
Top clinical trial sponsors for IMO-2125

See all IMO-2125 clinical trials

US Patents for IMO-2125

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IMO-2125 ⤷  Try it Free Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA) ⤷  Try it Free
IMO-2125 ⤷  Try it Free Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA) ⤷  Try it Free
IMO-2125 ⤷  Try it Free Immune modulation with TLR9 agonists for cancer treatment IDERA PHARMACEUTICALS, INC. (Exton, PA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
Medtronic
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.